|
1
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Talukdar F, di Pietro M, Secrier M,
Moehler M, Goepfert K, Lima SSC, Pinto LFR, Hendricks D, Parker MI
and Herceg Z: Molecular landscape of esophageal cancer:
Implications for early detection and personalized therapy. Ann N Y
Acad Sci. 1434:342–359. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yu P, Huang B, Shen M, Lau C, Chan E,
Michel J, Xiong Y, Payan DG and Luo Y: p15(PAF), a novel PCNA
associated factor with increased expression in tumor tissues.
Oncogene. 20:484–489. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jain M, Zhang L, Patterson EE and Kebebew
E: KIAA0101 is overexpressed, and promotes growth and invasion in
adrenal cancer. PLoS One. 6:e268662011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng Y, Li K, Diao D, Zhu K, Shi L, Zhang
H, Yuan D, Guo Q, Wu X, Liu D and Dang C: Expression of KIAA0101
protein is associated with poor survival of esophageal cancer
patients and resistance to cisplatin treatment in vitro. Lab
Invest. 93:1276–1287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang T, Guo J, Gu J, Chen K, Wang Z, Li
H, Wang G and Wang J: KIAA0101 is a novel transcriptional target of
FoxM1 and is involved in the regulation of hepatocellular carcinoma
microvascular invasion by regulating epithelial-mesenchymal
transition. J Cancer. 10:3501–3516. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kong X, Gong S, Su L, Li C and Kong Y:
Expression signatures and roles of MicroRNAs in human oesophageal
adenocarcinomas. J Cell Mol Med. 22:123–130. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng Q, Zhang H, Yao D, Chen WD and Wang
YD: Emerging role of non-coding RNAs in esophageal squamous cell
carcinoma. Int J Mol Sci. 21:2582019. View Article : Google Scholar
|
|
11
|
Chen P, Quan J, Jin L, Lin C, Xu W, Xu J,
Guan X, Chen Z, Ni L, Yang S, et al: MiR-216a-5p acts as an
oncogene in renal cell carcinoma. Exp Ther Med. 15:4039–4046.
2018.PubMed/NCBI
|
|
12
|
Yonemori K, Seki N, Idichi T, Kurahara H,
Osako Y, Koshizuka K, Arai T, Okato A, Kita Y, Arigami T, et al:
The microRNA expression signature of pancreatic ductal
adenocarcinoma by RNA sequencing: Anti-tumour functions of the
microRNA-216 cluster. Oncotarget. 8:70097–70115. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chai L and Yang G: MiR-216a-5p targets
TCTN1 to inhibit cell proliferation and induce apoptosis in
esophageal squamous cell carcinoma. Cell Mol Biol Lett. 24:462019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Lin P, Zou JY, Zou G, Wang WZ,
Liu YL, Zhao HW and Fang AP: MiR-216a-5p act as a tumor suppressor,
regulating the cell proliferation and metastasis by targeting PAK2
in breast cancer. Eur Rev Med Pharmacol Sci. 23:2469–2475.
2019.PubMed/NCBI
|
|
15
|
Ji Q, Xu X, Li L, Goodman SB, Bi W, Xu M,
Xu Y, Fan Z, Maloney WJ, Ye Q and Wang Y: miR-216a inhibits
osteosarcoma cell proliferation, invasion and metastasis by
targeting CDK14. Cell Death Dis. 8:e31032017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang D, Li Y, Zhang C, Li X and Yu J:
MiR-216a-3p inhibits colorectal cancer cell proliferation through
direct targeting COX-2 and ALOX5. J Cell Biochem. 119:1755–1766.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia H, Ooi LL and Hui KM:
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets
PTEN and SMAD7 to promote drug resistance and recurrence of liver
cancer. Hepatology. 58:629–641. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang RT, Xu M, Xu CX, Song ZG and Jin H:
Decreased expression of miR216a contributes to non-small-cell lung
cancer progression. Clin Cancer Res. 20:4705–4716. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, et
al: Esophageal and esophagogastric junction cancers, version
2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr
Canc Netw. 17:855–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan D, Zhu K, Dang C, Zheng Y, Yan R, Shi
L and Li K: NS5ATP9 mRNA levels in peripheral blood mononuclear
cells predict prognosis in patients with gastric cancer. Med Oncol.
31:1062014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang H, Fan JH and Qiao YL: Epidemiology,
etiology, and prevention of esophageal squamous cell carcinoma in
China. Cancer Biol Med. 14:33–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Warbrick E: A functional analysis of
PCNA-binding peptides derived from protein sequence, interaction
screening and rational design. Oncogene. 25:2850–2859. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Povlsen LK, Beli P, Wagner SA, Poulsen SL,
Sylvestersen KB, Poulsen JW, Nielsen ML, Bekker-Jensen S, Mailand N
and Choudhary C: Systems-wide analysis of ubiquitylation dynamics
reveals a key role for PAF15 ubiquitylation in DNA-damage bypass.
Nat Cell Biol. 14:1089–1098. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Emanuele MJ, Ciccia A, Elia AE and Elledge
SJ: Proliferating cell nuclear antigen (PCNA)-associated
KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting
complex/cyclosome substrate. Proc Natl Acad Sci USA. 108:9845–9850.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu L, Chen X, Xie S, Zhang C, Qiu Z and
Zhu F: Variant 1 of KIAA0101, overexpressed in hepatocellular
carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53
activation. Hepatology. 56:1760–1769. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hosokawa M, Takehara A, Matsuda K, Eguchi
H, Ohigashi H, Ishikawa O, Shinomura Y, Imai K, Nakamura Y and
Nakagawa H: Oncogenic role of KIAA0101 interacting with
proliferating cell nuclear antigen in pancreatic cancer. Cancer
Res. 67:2568–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kais Z, Barsky SH, Mathsyaraja H, Zha A,
Ransburgh DJ, He G, Pilarski RT, Shapiro CL, Huang K and Parvin JD:
KIAA0101 interacts with BRCA1 and regulates centrosome number. Mol
Cancer Res. 9:1091–1099. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Severgnini M, Sherman J, Sehgal A,
Jayaprakash NK, Aubin J, Wang G, Zhang L, Peng CG, Yucius K, Butler
J and Fitzgerald K: A rapid two-step method for isolation of
functional primary mouse hepatocytes: Cell characterization and
asialoglycoprotein receptor based assay development.
Cytotechnology. 64:187–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu K, Diao D, Dang C, Shi L, Wang J, Yan
R, Yuan D and Li K: Elevated KIAA0101 expression is a marker of
recurrence in human gastric cancer. Cancer Sci. 104:353–359. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L and Ma H: MicroRNA-216a inhibits the
growth and metastasis of oral squamous cell carcinoma by targeting
eukaryotic translation initiation factor 4B. Mol Med Rep.
12:3156–3162. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang S, Chen X and Tang M: MicroRNA-216a
inhibits pancreatic cancer by directly targeting Janus kinase 2.
Oncol Rep. 32:2824–2830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fadejeva I, Olschewski H and Hrzenjak A:
MicroRNAs as regulators of cisplatin-resistance in non-small cell
lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang XX, Deng LH, Chen WW, Shi N, Jin T,
Lin ZQ, Ma Y, Jiang K, Yang XN and Xia Q: Circulating microRNA 216
as a marker for the early identification of severe acute
pancreatitis. Am J Med Sci. 353:178–186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Link A, Becker V, Goel A, Wex T and
Malfertheiner P: Feasibility of fecal microRNAs as novel biomarkers
for pancreatic cancer. PLoS One. 7:e429332012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu FY, Zhou SJ, Deng YL, Zhang ZY, Zhang
EL, Wu ZB, Huang ZY and Chen XP: MiR-216b is involved in
pathogenesis and progression of hepatocellular carcinoma through
HBx-miR-216b-IGF2BP2 signaling pathway. Cell Death Dis.
6:e16702015. View Article : Google Scholar : PubMed/NCBI
|
